Back
Value Line 10K Form
Buy
57
VALU
Value Line
Last Price:
55.05
Seasonality Move:
6.28%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-03-15 | 10Q | VALU/Value Line Quarterly |
| 2023-12-15 | 10Q | VALU/Value Line Quarterly |
| 2023-09-12 | 10Q | VALU/Value Line Quarterly |
| 2023-03-14 | 10Q | VALU/Value Line Quarterly |
| 2022-12-12 | 10Q | VALU/Value Line Quarterly |
| 2022-09-14 | 10Q | VALU/Value Line Quarterly |
Receive VALU News And Ratings
See the #1 stock for the next 7 days that we like better than VALU
VALU Financial Statistics
Sales & Book Value
| Annual Sales: | $37.49M |
|---|---|
| Cash Flow: | $4.77M |
| Price / Cash Flow: | 27.86 |
| Annual Sales: | $9.97 |
| Price / Book: | 5.21 |
Profitability
| EPS (TTM): | 2.12000 |
|---|---|
| Net Income (TTM): | $20.04M |
| Gross Margin: | $22.64M |
| Return on Equity: | 22.52% |
| Return on Assets: | 14.92% |
Value Line Earnings Forecast
Key Value Line Financial Ratios
- The Gross Profit Margin over the past 41 years for VALU is 60.38%.
- The Selling, General & Administrative Expenses for VALU have been equal to 36.00% of Gross Profit Margin.
- The Research & Development expenses have been 0.00% of Revenue.
- The Interest Expense is 0.00% of Operating Income.
- The Net Earning history of VALU is 50.73% of Total Revenues.
- Per Share Earnings over the last 41 years have been positive in 24 years.
Value Line Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Capital Markets |
| Sector: | Financials |
| Current Symbol: | VALU |
| CUSIP: | 920437 |
| Website: | valueline.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 3.17 |
| Quick Ratio: | 3.12 |
Price-to-Earnings
| Trailing P/E Ratio: | 25.7 |
|---|---|
| Forward P/E Ratio: | 0 |
VALU Technical Analysis vs Fundamental Analysis
Buy
57
Value Line (VALU)
is a Buy
Is Value Line a Buy or a Sell?
-
Value Line stock is rated a Buy
The current Value Line [VALU] share price is $56.32. The Score for VALU is 57, which is 14% above its historic median score of 50, and infers lower risk than normal.